logo

Avrobio, Inc. (AVRO)



Trade AVRO now with
  Date
  Headline
2/7/2019 8:25:19 AM Wedbush Reiterates AVROBIO, INC. (AVRO) At Outperform With $43 Price Target
2/6/2019 9:05:48 AM AVROBIO Announces Updated Clinical Data From Phase 1 And Phase 2 Studies For AVR-RD-01 Gene Therapy For Fabry Disease
1/18/2019 7:06:32 AM AVROBIO Announces Acceptance Of IND Application For Phase 1/2 Clinical Trial For AVR-RD-04 Gene Therapy For Cystinosis
1/7/2019 7:07:22 AM AVROBIO Appoints Philip Vickers To Its Board
12/19/2018 7:13:01 AM AVROBIO Gets Orphan-Drug Designation From US FDA For AVR RD 01 For Treatment Of Fabry Disease
12/18/2018 7:08:06 AM AVROBIO Announces Grant Of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
11/15/2018 6:30:18 AM Wedbush Is Lowering AVROBIO, INC. (AVRO) FY19 Estimate To -2.54 From -2.37
11/15/2018 6:30:04 AM Wedbush Is Lowering AVROBIO, INC. (AVRO) Q4 19 Estimate To -0.62 From -0.58
11/15/2018 6:29:50 AM Wedbush Is Cutting AVROBIO, INC. (AVRO) Q3 19 Estimate To -0.61 From -0.55
11/15/2018 6:29:38 AM Wedbush Is Lowering AVROBIO, INC. (AVRO) Q2 19 Estimate To -0.68 From -0.64
11/15/2018 6:29:25 AM Wedbush Is Cutting AVROBIO, INC. (AVRO) Q1 19 Estimate To -0.63 From -0.60
11/15/2018 6:29:11 AM Wedbush Is Raising AVROBIO, INC. (AVRO) FY18 Estimate To -4.57 From -4.70
11/15/2018 6:28:54 AM Wedbush Is Increasing AVROBIO, INC. (AVRO) Q4 18 Estimate To -0.60 From -0.64
11/15/2018 6:28:29 AM Wedbush Reiterates AVROBIO, INC. (AVRO) At Outperform With $43 Price Target
11/13/2018 8:30:40 AM AVROBIO Q3 Net Loss $11.6 Mln